Tempus AI expands with Deep 6 AI acquisition

Published 11/03/2025, 22:22
Tempus AI expands with Deep 6 AI acquisition

CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a company at the forefront of applying artificial intelligence in healthcare to advance precision medicine, has announced the acquisition of Deep 6 AI. With a market capitalization of $7.8 billion and impressive revenue growth of 30% over the last twelve months, Tempus continues to expand its footprint. This move is set to enhance Tempus’s capabilities in supporting healthcare organizations and life sciences companies with AI-driven research platforms. According to InvestingPro data, the company maintains a healthy liquidity position with a current ratio of 2.29.

Deep 6 AI’s technology focuses on streamlining clinical trials by leveraging AI to match patients with trials using real-time data from electronic medical records. This acquisition is poised to expand Tempus’s existing network, which already encompasses a vast library of multimodal data and an operating system designed to make that data useful for healthcare providers. The market has responded cautiously to this strategic move, with the stock declining 14% over the past week. For detailed analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks.

Eric Lefkofsky, Founder and CEO of Tempus, stated that Deep 6 AI’s robust integration infrastructure will complement Tempus’s efforts to optimize patient care. The acquisition is expected to broaden Tempus’s reach by adding more providers to its platform and enhancing the deployment of applications like Next, which assists physicians in addressing care gaps, and TIME, which aids patients in finding clinical trials.

Tempus is known for its AI-enabled precision medicine solutions that assist physicians in providing personalized patient care. The company also supports the discovery, development, and delivery of therapeutics, aiming to improve treatments for future patients based on the data gathered from previous cases.

While the press release includes forward-looking statements about the potential benefits of the acquisition and Tempus’s future operations, these statements are subject to various risks and uncertainties. Analysts project continued losses for the company in the coming year, with an EPS forecast of -$0.52. As with any business development, the integration of Deep 6 AI into Tempus’s operations and the realization of expected benefits will be closely watched by investors and industry observers. InvestingPro subscribers can access additional financial health metrics and 7 more exclusive ProTips to make informed investment decisions.

This news is based on a press release statement and provides a glimpse into Tempus’s strategic direction as the company continues to expand its role in the healthcare technology sector.

In other recent news, Tempus AI Inc has reported a strong fourth-quarter revenue growth of 35.8% year-over-year, reaching $700 million. Despite this robust performance, the company’s earnings per share (EPS) came in at -0.18. Tempus AI has revised its 2025 revenue guidance to approximately $1.24 billion, slightly above the previous estimate of $1.23 billion. The company completed the acquisition of Ambry Genetics, which is expected to contribute to Tempus AI’s projected growth in core revenue by over 30% year-over-year.

Analyst reactions to these developments have been mixed. Stifel analysts maintained a Hold rating on Tempus AI shares, with a $65 price target, citing fair market valuation compared to peers. On the other hand, JPMorgan downgraded the stock from Overweight to Neutral but raised the price target to $55, acknowledging the company’s sustainable Data & Service Revenue and increasing profitability. The company also launched the Olivia AI personal health app, expanding its product offerings in the healthcare sector.

Tempus AI’s management remains optimistic about the company’s growth trajectory, with expectations for adjusted EBITDA of $5 million for the current year. However, the company faces challenges, such as a projected slowdown in Ambry Genetics’ growth and questions about total contract value for data services. Despite these hurdles, Tempus AI continues to focus on innovation and strategic partnerships to drive future growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.